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ABSTRACT
Circadian mRNA oscillations are the main feature of
core clock genes. Among them, period 2 is a key
component in negative-feedback regulation, show-
ing robust diurnal oscillations. Moreover, period 2
has been found to have a physiological role in the
cell cycle or the tumor suppression. The present
study reports that 3’-untranslated region (UTR)-
dependent mRNA decay is involved in the regulation
of circadian oscillation of period 2 mRNA. Within the
mper2 3’UTR, both the CU-rich region and polypy-
rimidine tract-binding protein (PTB) are more
responsible for mRNA stability and degradation
kinetics than are other factors. Depletion of PTB
with RNAi results in mper2 mRNA stabilization.
During the circadian oscillations of mper2, cytoplas-
mic PTB showed a reciprocal expression profile
compared with mper2 mRNA and its peak amplitude
was increased when PTB was depleted. This report
on the regulation of mper2 proposes that post-
transcriptional mRNA decay mediated by PTB is a
fine-tuned regulatory mechanism that includes
dampening-down effects during circadian mRNA
oscillations.
INTRODUCTION
The suprachiasmatic nucleus (SCN) in the hypothalamus
governs circadian clock oscillation in mammals (1,2).
Circadian oscillations in response to various stimuli have
been demonstrated not only at the SCN in the brain but
also in various peripheral tissues, and even in cultured cell
lines (3). These oscillation mechanisms are regulated by a
transcriptional negative feedback loop involving binding
of the BMAL1/CLOCK heterodimer to the E/E0 box in
the promoter region of clock genes and feedback inhibi-
tion by accumulated Per-Cry protein heterodimer, and
by post-translational modiﬁcation of protein products by
cellular kinases and degradation by proteasomes (4).
Among the core clock gene family, period 2 and period
1 are responsive to photic entrainment from the retina to
the SCN (1,2,5,6). Robust circadian oscillations of per2
mRNA and Per2 protein are not only evident in the
brain, but are also present in various peripheral tissues
(7,8). period 2 is also known to have a physiological role
in tumor suppression (9,10) and feeding/energy metabo-
lism (11). For these reasons, period 2 regulation has been
studied more than any other circadian molecule at the
translational or post-translational level; however, no
reports have demonstrated regulation at the level of
mRNA degradation.
In general, mRNA degradation is controlled by two
major components, the mRNA binding motif (cis-acting
element, CAE) and its binding partners (trans-acting fac-
tors, TAFs) (12); thus mRNAs containing a CAE in their
30-UTR may be regulated by various binding factors. The
AU-rich element (ARE) in the 30-UTR is well character-
ized and is the most commonly used CAE in post-
transcriptional regulation. The fate of the mRNA is
therefore largely determined by associations between the
ARE and its binding factors (13).
The polypyrimidine tract-binding protein (PTB),
also known as heterogeneous nuclear ribonucleoprotein
(hnRNP) I, is a cellular RNA-binding protein that is
abundant in many tissues. PTB binds to oligopyrimidine
tracts in introns and regulates negative or positive exon
deﬁnition in the diﬀerential splicing of various cellular
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involved in other aspects of RNA metabolism, such as
modulation of polyadenylation eﬃciency (18) and the sta-
bility of nitric oxide synthase mRNA during inﬂammation
(19). Moreover, PTB represents the prototype of a hetero-
geneous group of cellular RNA-binding proteins that are
directly involved in the regulation of translation, a func-
tion that was discovered during investigation of transla-
tion of picornaviruses (20,21). Activated cytoplasmic PTB
appears to aﬀect the nutrient-dependent stabilization
of mRNAs involved in insulin synthesis and secretion
(22,23). In addition, regulation of protein kinase A by
various hormone signaling pathways promotes nucleocy-
toplasmic relocalization of PTB (24), suggesting a direct
role of PTB in the regulation of mRNA stability.
Circadian rhythms have been studied using transgenic
or knock-out animal models to investigate the molecular
mechanisms underlying the control of gene expression at
the transcriptional level (25–28), whereas transcriptional
feedback regulation is considered a representative model
for understanding the phenomenum of circadian oscilla-
tion, little is known about the role of post-transcriptional
regulation in circadian rhythm. Several reports have
demonstrated oscillatory mechanisms mediated by post-
transcriptional regulation in the fruit ﬂy (29,30) and
recent studies in mammalian systems revealed that regula-
tion of mRNA decay is actively involved in circadian
oscillation (31,32). Kojima et al. also reported post-
transcriptional regulation of the core clock gene PER1;
however, this occurred through modulation of the transla-
tional process. Regulatory mechanisms acting at many
diﬀerent stages from core clock gene transcription to
protein activation allow ﬁnely-tuned rhythmic oscillation.
With the ongoing addition of new molecular components
to the core model, our understanding of the oscillation
mechanism is becoming more comprehensive (33).
The present reports proposes that mRNA stability of
the circadian core clock gene mper2 is modulated by the
30UTR and cytoplasmic PTB, and that mRNA instability
is mediated by cytoplasmic increases in PTB protein. Our
study also suggests that cytoplasmic PTB-mediated
mRNA decay plays an important role in the modulation




mper2 30-UTRs were ampliﬁed from full-length mouse
per2 cDNA using speciﬁc primers (GenBank accession
number NM011066). Ampliﬁcation of cDNA was per-
formed with pfu polymerase (Solgent) and conﬁrmed by
sequencing. To generate pcNAT-30-UTR (mper2 30-UTR
inserted into 30-UTR of AANAT), pGL3-30-UTR, and
pSK0-30-UTR, PCR products were digested with EcoRI/
XbaI and inserted into the EcoRI/XbaI site of pcNAT
control which expresses rat aanat without 30-UTR (32),
modiﬁed pGL3-control (Promega), and modiﬁed pSK0
(32) using EcoRI/XbaI site, respectively. To dissect
the regions involved in post-transcriptional regulation,
serially deleted and mutated 30-UTR fragments were
cloned into the 30-UTR region of the reporter using the
EcoRI/XbaI digestion site.
Cellculture anddexamethasone treatment
CHO-K1 cells were cultured in DMEM/F-12 (Welgene)
with 10% bovine calf serum (Hyclone)/1% antibiotics
(Welgene) and HEK 293T cells in DMEM (Welgene)
with 10% fetal bovine serum (Welgene)/1% antibiotics.
NIH-3T3 and HeLa cells were cultured in DMEM with
10% fetal bovine serum/1% antibiotics, and maintained in
humidiﬁed 95% air/5% CO2 incubator.
Circadian oscillation of NIH 3T3 cells was synchro-
nized by treatment with 100nM dexamethasone for 2h.
Instead of the usual single dexamethasone treatment,
dexamethasone shock was applied twice at  24h and 0h
before the onset of the circadian period, and cells were
monitored throughout the following 2 days.
Transient expression, reporter assay, and mRNA
quantification
For expression of the reporter constructs, cells were
counted and plated in a 24-well plate at a density of 10
5
cells/well. After 24h, 0.7mg DNA was introduced into
each well by lipid-mediated transfection using Welfect
transfection reagent (Welgene) following the manufac-
turer’s manual. Post-transfected cells were treated with
the transcription blocker actinomycin D (5mg/ml) at
time 0h and harvested at indicated times thereafter.
AANAT assay and luciferase assay for reporter activity
were performed as previously reported (34) and follow-
ing the manufacturer’s manual, respectively. mRNA
levels of reporters were detected by northern blot analysis
with an [a-
32P] dCTP(NEN)-labeled speciﬁc probe or
by quantitative real-time PCR using a MyIQ single time
real-time detector system (Bio-Rad) with SYBR Green
PCR mixture (Bio-Rad, Takara) as described previously
(31). Speciﬁc primer pairs for ﬁreﬂy luciferase, endogen-
ous mper2, mgapdh, mrpl32, and mtbp were used (primer
sequences are provided in supplementary Table2).
Establishment ofastable cell line
A pP2PL-30-UTR target vector was constructed by repla-
cing the CMV promoter region with the full length mper2
promoter (GenBank accession no. AF491941) using BglII/
BamHI and replacing the AANAT ORF with the ﬁreﬂy
luciferase ORF using the BamHI/XhoI site within the
pcNAT-per2 30-UTR. NIH-3T3 cells were transfected
with target vector by the calcium phosphate precipitation
method and transfected cells were selected by incubation
in selection medium containing G418 (700mg/ml). Selected
colonies were screened by reverse transcriptase–polymer-
ase chain reaction (RT–PCR) to conﬁrm stable expression
of reporter mRNA.
Invitro binding/UV cross-linking/immunoprecipitation
To identify proteins speciﬁcally bound to mper2 30-UTR,
in vitro binding and UV cross-linking assays were per-
formed as described previously (35). pSK0-30-UTR
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based in vitro transcription (Promega, Roche). [a-
32P]
UTP (NEN)-abeled RNAs and unlabeled competitor
RNA were transcribed in vitro using T7 RNA polymerase
and XbaI linearized pSK0-30-UTR constructs. Equal
molar amount of labeled RNAs were incubated with
15mg nuclear extracts or 30mg cytoplasmic extract of
either HEK293T cell or mouse SCN for 20min at 308C.
The RNA-protein binding reaction was carried out in a
30ml reaction mixture containing 0.5mM DTT, 5mM
HEPES (pH 7.6), 75mM KCl, 2mM MgCl2, 0.1mM
EDTA, 4% glycerol, 20 U RNasin (Promega), and 4mg
yeast tRNA. When indicated, unlabeled competitor tran-
scripts were included in the reaction mixture. After incu-
bation, the samples were UV-irradiated on ice for 10min
with a CL-1000 UV-crosslinker (UVP). Unbound RNAs
were digested with 5ml RNase cocktail (2.5ml RNase A
[10mg/ml] and 2.5ml RNase T1 [100U/ml; Roche]) at
378C for 1h. The reaction mixtures were analysed by
SDS-PAGE and autoradiography.
For immunoprecipitation, RNase digested lysates were
incubated with speciﬁc antibodies or pre-immune serum
for the negative control. After overnight incubation,
Protein G agarose beads (Amersham bioscience) were
added to the sample, which was further incubated for
3h. Washed beads were analysed by SDS-PAGE and
autoradiography.
Invitro decay assay
In vitro decay assay was performed as described previously
(36). Brieﬂy, in vitro transcribed [a-
32P] UTP-labeled/
capped mRNAs were incubated with cytoplasmic S100
lysate with or without puriﬁed recombinant PTB
protein (a gift of Dr Jang) or competitor RNA for
the indicated time. Reactions were terminated by addi-
tion of urea lysis buﬀer (7M urea; 2%SDS; 350mM
NaCl;10mMEDTA;10mM Tris-Cl pH 7.5). Phenol-
chloroform extracted probes were dissolved in 95%
formamide RNA loading buﬀer. Samples were separ-
ated in 6% SDS-PAGE/7M Urea, then analysed by
autoradiography.
RNA interference
siRNA and DNA based shRNA were designed for endo-
genous PTB knock down. Two target sites were selected
by the web-based siRNA design programs: http://www.
dharmacon.com/DesignCenter/DesignCenterPage.aspx
http://www.ambion.com/techlib/misc/siRNA_tools.html
UTR target siRNAs for PTB were synthesized as
recommended (Samchully Pharm.). Selected siRNA
sequences are given in supplementary Table 1. DNA-
based shRNA was generated using the H1 promoter
from a modiﬁed pShuttle vector transfection system, as
described previously (35). PAGE puriﬁed oligonucleotides
were annealed in 2 SSC and subcloned into the BglII/
HindIII site. The oligonucleotide sequences are given in
supplementary Table 1. To express the shRNA, cells were
plated in a 24-well plate at a density of 10
5 cells/well. After
24h, 0.7mg DNA was introduced into each well by lipid-
mediated transfection using Welfect transfection reagent
(Welgene) following the manufacturer’s instructions. For
siRNA transfection into NIH 3T3 cells, a microporator
(Digital-Bio) was used as recommended by the manufac-
turer with conditions of 1300V/20ms/2 pulses 12h prior
to dexamethasone shock.
Cytoplasmic/nuclear protein preparation and
immunoblot analysis
Fractionation of CHO-K1 cells, NIH-3T3 cells, and
mouse SCN into cytoplasmic and nuclear extracts was
performed as described previously (35,37). Immunoblot
analyses were performed with polyclonal anti-PTB, mono-
clonal anti-14-3-3x, and monoclonal anti-GAPDH (ICN)
as primary antibodies. HRP-conjugated species-speciﬁc
secondary antibodies (KPL) were visualized using a
SUPEX ECL solution kit (Neuronex) and a LAS-
4000 chemiluminescence detection system (FUJIFILM),
and acquired images were analysed using Image
Gauge (FUJIFILM) according to the manufacturer’s
instructions.
RESULTS
mper2 mRNA isdegraded in aphase-dependent manner
mRNA oscillation of mper2 is well established in various
tissues including the brain and even in ﬁbroblast cell lines
(34,35). To elucidate the mechanism of phase-dependent
mRNA decay the mper2 mRNA oscillation pattern was
monitored in the NIH 3T3 ﬁbroblast cell line after syn-
chronization by dexamethasone treatment. Under our
modiﬁed treatment conditions, robust mper2 mRNA oscil-
lation could be observed (Figure 1A) and the mRNA pro-
ﬁle was not signiﬁcantly diﬀerent from the pattern
obtained after a classic single dexamethasone treatment
(data not shown) (40). In this oscillatory condition,
mRNA degradation kinetics were compared in the rising
and declining phases during day 2 (shaded box in
Figure 1A). To avoid any inﬂuence of media change (3),
we monitored all proﬁles during the 2nd day after induc-
tion instead of the 1st day. As shown in Figure 1B, when
actinomycin D was used to inhibit transcription, more
dramatic decay was observed in the declining phase
(closed triangles) than in the rising phase (closed squares).
The role of transcriptional regulation in circadian mRNA
oscillation is well established, and such oscillation is gen-
erally thought to be mainly governed by the action of
transcription factors such as the BMAL1/CLOCK hetero-
dimer. However, our results indicate that mRNA decay
also plays a role in the circadian mRNA regulatory
mechanism.
The mper2 3’-UTRplays arole inits own degradation
Because mRNA decay is typically mediated by the
30-UTR, we introduced serially deleted NAT(serotonin-
N-acetyltransferase) reporter constructs containing var-
ious lengths of the mper2 30-UTR into CHO-K1 cells
(32) to determine the critical cis-acting element. In cells
treated with the transcription blocker actinomycin D
for 6h, (Figure 2A) the full-length (1889nts) and 30-end
28 Nucleic Acids Research, 2009, Vol. 37,No. 1(449nts) of mper2 30-UTR triggered dramatic decreases in
mRNA levels to 34.9% and 54.9% of the untreated level
respectively, whereas the reporter gene alone and reporter
fused to a construct with a 30-end truncation (1263 nts)
were relatively stable (99 and 75.3%, respectively). This
diﬀerence in stability was also observed at the level of the
reporter protein (supplementary Figure S1). These trends
in stability were also observed in the NIH 3T3 cell line
which is typically used as a circadian model system (data
not shown).
Actinomycin D pulse-chasing was applied to analyse
reporter mRNA decay kinetics following co-transfection
with a control reporter lacking the 30-UTR and a 30-UTR
fused reporter (Figure 2B). When quantiﬁed relative to
expression of the control construct, reporter genes fused
to full-length or 30-end UTR (30-U449) had half-lives of
 3h or  4h, respectively, whereas the 30-end truncated
UTR (30-UTR1263) had a much longer half-life
(Figure 2C).
To examine the eﬀect of the 30-UTR on mRNA oscilla-
tion, we constructed stable NIH 3T3 cell lines that express
vectors containing the endogenous mouse per2 promoter,
ﬁreﬂy luciferase open reading frame (ORF), and either
full-length or 30-truncated mper2 30-UTR. Although sev-
eral groups have reported that canonical or non-canonical
putative E/E’ box or D box elements in the promoter
of clock genes are suﬃcient to generate robust oscillation
(27,33), we used the full length mper2 promoter ( 1.7kb)
cloned from genomic DNA to more accurately reﬂect the
endogenous transcriptional activity of mper2 (Figure 2D).
As shown in Figure 2E, cells expressing vector with full-
length 30-UTR displayed a similar oscillation pattern to
that of endogenous mper2, although the phase was slightly
advanced. In contrast, cells expressing the 30-end-deleted
UTR showed an unusual pattern of mRNA oscillation,
indicating that the 30-truncated UTR is not suﬃcient to
generate an oscillation pattern similar to the endogenous
rhythm of mper2. The unusual oscillation of the truncated
mRNA may be the results of mRNA stabilization. When
we tested the oscillation proﬁle of a reporter lacking per2
promoter the mRNA did not show a natural oscillating
proﬁle(data not shown) indicating that transcriptional reg-
ulation is required for circadian mRNA oscillation. These
results suggest that the 30-UTR, in particular the 30-end
sequence, can modulate mper2 mRNA oscillation in asso-
ciation with transcriptional regulation.
PTBbinds to pyrimidine tract in mper2 3’-endsequence
We next investigated mRNA binding proteins to identiﬁe
the protein(s) responsible for the changes in mRNA sta-
bility associated with truncation of mper2 30-UTR. The
mRNA binding proﬁle was analyzed by an in vitro bind-
ing/UV cross-linking assay using in vitro transcribed
mRNAs. Although the contribution of indirectly bound
proteins could not be excluded, the direct binding proﬁle
of many proteins was examined. One protein of  57kDa
exhibited enhanced binding to the full-length 30-UTR and
30-U449, but not to the 30-end truncated UTR (Figure 3A,
supplementary Figure S2A). These results suggest that the
30-end region of mper2 mRNA 30-UTR functions as a
critical region to destabilize mRNA and provides a bind-
ing site for the  57kDa protein, which acts as a trans-
acting factor. To identify the interacting protein, we used
in vitro transcribed biotinylated mper2 30-UTR to isolate
RNA-bound proteins, which were separated by SDS-
PAGE (data not shown). The 57kDa protein (p57) was
analysed by MALDI-TOF mass spectrometry as described
previously (35) yielding a strong match to the polypyimi-
dine tract binding protein (PTB). To conﬁrm the identity
of the protein and its binding to mper2 30-UTR, immuno-
precipitation was performed on the in vitro binding/UV
cross-linked extract using a polyclonal anti-PTB antibody.
As shown in Figure 3B, PTB was detected by the anti-
body, indicating that PTB interacts directly with mper2
Figure 1. mper2 mRNA is degraded in a phase dependent manner.
(A) Oscillation of endogenous mper2 mRNA was measured by
quantitative real-time PCR in NIH 3T3 cells. NIH 3T3 cells were trea-
ted with 100nM dexamethasone twice for 2h at  24 and 0h to
synchronize the circadian oscillation. Total RNA (1mg) from
each time point was subjected to quantitative real time RT–PCR with
speciﬁc oligonucleotides for mper2 and mtbp (TATA box binding pro-
tein) as a normalizing control. All results are expressed as the
mean SEM of three independent experiments. (B) mRNA degrada-
tion kinetics were measured during both declining (closed triangles) and
rising (closed squares) phases in the 2nd day after dexamethasone treat-
ment (shaded box in Figure 1A). Cells were treated with 5mM actino-
mycin D at 32h, during the rising phase, and at 40h, during the
declining phase, and then harvested at 2h intervals. Total RNA
(1mg) was subjected to quantitative real time RT–PCR with speciﬁc
primer pairs against mper2,o rmrpl32 as a normalizing control.
All results are expressed as the mean SEM of three independent
experiments.
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same experiment was repeated with nuclear extract of the
SCN of the hypothalamus (supplementary Figures S2A
and S2B); however, it was not clear whether the bound
PTB was the ubiquitous PTB isoform or neuronal PTB
(nPTB) which is speciﬁcally expressed in the brain.
We also conﬁrmed binding of PTB to biotin-labelled
mper2 30-UTR by immunoblotting with anti-PTB anti-
body and biotin-streptavidin aﬃnity puriﬁcation
(Figure 3C). Binding of PTB to full length 30-UTR or
the 30-end region was dramatically inhibited by competi-
tion with unlabeled UTR (Figure 3C lane3, supplementary
Figure 2. mper2 30-UTR is responsible for its own mRNA degradation.(A) Northern blot analysis of NAT reporter: 30-UTR constructs. CHO-K1
cells were transiently transfected by electroporation with NAT reporter alone or NAT reporter fused to serially deleted mper2 30-UTR (shown in
schematic diagrams, the numbers indicate nucleotide lengths of the 30-UTR). b-gal was used as a transfection control. Transfected cells were
incubated for 12h before treatment with 5mM actinomycin D. Total RNA (10mg) was hybridized with a probe speciﬁc for AANAT coding sequence.
Et-Br stained 28S rRNA provided a loading control. Odd numbered lanes, 0h; even numbered lanes, after 6h treatment with 5mM actinomycin D.
(B) Degradation kinetics and half-life of 30-UTR:reporter constructs were analysed by actinomycin D pulse chasing and northern blot hybridization.
Experimental schemes are the same as in panel A. Representative results of three independent experiments are shown. (C) The band intensities in
panel B were quantiﬁed by phosphoimaging and normalized to the intensity of cotransfected AANAT control in each lane. The graph shows the
mean SEM of three independent experiments. (D) Diagrams of recombined reporter constructs consisting of mper2 promoter ( 1.7kb), ﬁreﬂy
luciferase open reading frame, and either full-length mper2 30UTR or 30 region deleted mper2 UTR. (E) Fireﬂy luciferase mRNA expression from
stably recombined reporter vectors and endogenous mper2 mRNA were measured by quantitative real-time RT–PCR using cDNA harvested at 6h
(cell line) or 4h (endogenous mper2) intervals from stably transfected NIH 3T3 cell lines that were synchronized by treatment with dexamethazone.
All results are representative of three independent experiments from each selected line.
30 Nucleic Acids Research, 2009, Vol. 37,No. 1Figure S2E) and deoxyoligonucleotide #1, which is speci-
ﬁc for PTB binding (Figure 3B lane 2, 3C lane 4, under-
lined in Figure 3E, supplementary Figure S2D,
supplementary Table2) (41), but was unaﬀected by com-
petition with oligonucleotide #2 or #3 (data not shown).
Speciﬁc binding of PTB to the mper2 30-UTR end region
was also observed in a binding experiment with recom-
binant puriﬁed PTB4 protein (Figure 3D), in which
the binding capacity was shown to be concentration-
dependent (supplementary Figure S2C). These results
suggest that PTB directly binds to mper2 30-UTR and
that binding occurs preferentially on the 30-end region.
PTBdestabilizes mper2 mRNA 3’-UTR
Although PTB acts as a splicing regulator, several reports
have shown that PTB can also bind to 30-UTR regions and
stabilize target mRNAs (23,42,43). The eﬀect of PTB on
mper2 mRNA stability was examined by transient expres-
sion analysis using a 30-UTR containing reporter and
Figure 3. PTB binds to the pyrimidine tract in the mper2 30-UTR end sequence. (A) Each in vitro transcribed 30-UTR was subjected to in vitro
binding and UV cross-linking assay with CHO-K1 cytoplasmic extract. The arrow indicates the 57kDa protein that shows diﬀerential binding.
(B) In vitro binding/UV cross-linking/immunoprecipitation was performed with the 449nts 30-end region as described in Materials and Methods.
In lane 2 the reaction was co-incubated with 1mM competitor oligonucleotide #1, which speciﬁcally binds to PTB. Lanes 3 and 4 show immuno-
precipitation with polyclonal anti-PTB antibody or pre-immune serum (PIS), respectively. (C) The in vitro transcribed 30-U449 construct was labeled
with biotin-UTP and incubated with CHO-K1 cell cytoplasmic extract. Streptavidin-aﬃnity puriﬁed samples were separated by SDS-PAGE and
subjected to western blotting with anti-PTB antibody. Abundant PTB was detected in the reaction with biotin labeled mRNA (lane 2). PTB binding
decreased in the presence of a 3-fold excess of unlabeled mRNA (lane 3) or when 1mM deoxyoligonucloetide competitor #1 was added (lane 4;
speciﬁc binding of biotin-labeled oligonucleotide #1 to PTB is shown in lane 6) but was not aﬀected by oligonucleotide #2 (lane 5). (D) The
experiments in panels A and B were repeated with puriﬁed recombinant PTB4 protein. (E) Period 2 30-UTR end region of 449 nts. Competitor
oligonucleotide sequences are underlined and the authentic poly A signal is indicated in bold.
Nucleic Acids Research, 2009, Vol. 37, No. 1 31actinomycin D pulse-chase experiments in HeLa cells.
Depletion of endogenous PTB was successfully achieved
by targeted RNAi and could be ectopically rescued by
co-expression of GFP-PTB (Figure 4A upper panel).
When cytoplasmic PTB was knocked down by RNA inter-
ference, the reporter mRNA was very stable after treat-
ment with actinomycin D compared with controls or cells
that were rescued by GFP-PTB (Figure 4A). In addition,
the degradation kinetics of reporter mRNA after the acti-
nomycin D pulse were also inﬂuenced by PTB depletion
in NIH 3T3 cells (Figure4B upper panel). Transiently
expressed reporter mRNAs were stabilized by cotransfec-
tion with siRNA targeting PTB (Figure 4B, closed
squares), compared with transfection with control
siRNA (Figure4B, open squares). The destabilizing eﬀect
of PTB was also observed in an in vitro mRNA decay
assay (Figures 4C and 4D). A radio-labeled in vitro tran-
scribed 30-UTR probe was incubated with an S100 cyto-
plasmic extract of HeLa or NIH 3T3 cells. When puriﬁed
PTB4 protein was added to the reaction mixture, degrada-
tion occurred more rapidly (Figure 4C, closed squares)
than with the GST control (Figure 4C, open squares). In
contrast, when competitor oligonucleotide #1 was added
(41), PTB binding to mRNA was completely inhibited
(supplementary Figure S2D) and degradation kinetics
slowed down (Figure 4C, closed triangles). In addition,
mRNA decay was slower in the presence of PTB-depleted
NIH 3T3 S100 extract (Figure 4D, middle panel, closed
diamonds) and recovered when recombinant PTB was
added (Figure 4D, open diamonds). Together, these
results indicate that PTB has mRNA destabilizing activity
when it binds to mper2 30-UTR.
Cytoplasmic PTB showsreciprocal expression patternwith
mRNAoscillation
PTB plays a role in mRNA splicing to regulate excision of
certain exons (15,44) and PTB levels in the total cell lysate
of various cell lines is very high (data not shown). PTB is
predominantly localized in the nucleus where mRNA spli-
cing occurs; however, because cellular mRNA decay
mainly occurs in the cytoplasm we examined the cytoplas-
mic PTB level. Interestingly, the amount of cytoplasmic
PTB increased according to the speciﬁc period of circadian
time following 2h exposure of NIH 3T3 cells to dexa-
methasone (Figure 5A and supplementary Figure S3),
but the total level of PTB did not change (data not
shown). Furthermore, the pattern of cytoplasmic PTB
levels was almost reciprocal to that of mper2 mRNA
levels (Figure 5B). Immunostaining analysis conﬁrmed
the increase in levels of cytoplasmic PTB (Figure 5C).
To examine the amount of cytoplasmic PTB that bound
to mRNA, aliquots of the cytoplasmic protein fraction
from each time point were coincubated in vitro with radi-
olabeled mper2 30-UTR. Compared with other binding
proteins, the binding of cytoplasmic PTB to mRNA
increased during the phase of mRNA decline (6–12h)
(Figure 5D). Since decay of mature mRNA occurs
mainly in the cytoplasm, our results suggest that the
increase in cytoplasmic PTB and its binding to target
mRNA are responsible for the rapid decay of mper2
mRNA during the declining phase.
PTB down regulation affects mper2 mRNAcircadian
peak amplitude
The inﬂuence of PTB on mper2 mRNA stability and oscil-
lation was further examined by measuring the mper2
mRNA oscillation proﬁle in NIH 3T3 cells when PTB
was downregulated. Transfection wih siRNA eﬃciently
knocked down endogenous PTB proteins throughout the
experimental circadian period (Figure 6A). Interestingly,
PTB-depleted cells showed a signiﬁcant increase in peak
amplitude of mper2 mRNA expression (Figure 6B), but
did not exhibit changes in mper2 mRNA oscillation pat-
tern other than a slight advance of peak time compared
with cells treated with control siRNA. The mRNA level of
bmal1, the transcription activator of the mper2 gene, was
not signiﬁcantly diﬀerent between PTB-depleted cells and
control cells (data not shown), indicating that PTB acts
speciﬁcally at the post-transcription level on the 30-UTR
of mper2 mRNA. Taken together, these results show that
the cytoplasmic level of PTB plays a crucial role in regu-
lating mper2 mRNA stability and damping down the oscil-
lation rhythm, critical functions for the maintenance of a
robust mRNA oscillation pattern.
DISCUSSION
Post-transcriptional regulation in circadian per2
mRNA oscillation
Autonomous circadian biorhythms have been studied for
many years; however, we still do not fully understand the
regulation of such rhythms and it is generally assumed
that other molecular regulatory mechanisms must be
involved in addition to transcriptional negative feedback.
Although post-transcriptional regulation of circadian
rhythm in Drosophila was reported a decade ago (30),
its role in the mammalian circadian system has only
recently been revealed. Several reports have demonstrated
that post-transcriptional regulation is involved in active
mRNA decay in pineal gland melatonin biosynthesis
and in the oscillation of the core circadian gene mper3
(31,32). Translational regulation and miRNA involvement
were also reported in circadian rhythmicity (37,45,46). The
present study investigates the functional role of mRNA
decay in circadian mper2 gene regulation. mper2 mRNA
decay kinetics were veriﬁed using a modiﬁed synchroniza-
tion method, double-dexamethasone shock, in which an
additional 100nM dexamethasone shock was applied
24h prior to the standard treatment at 0h. This technique
gave reproducible mRNA (Figure 1A) and cytoplasmic
PTB (Figure 5A) proﬁles and the mRNA proﬁle induced
by our modiﬁed treatment was not signiﬁcantly diﬀerent
from that reported previously (40). Although transcrip-
tional activation and repression of circadian genes is the
main regulatory mechanism (47), our results indicate that
mRNA stability also plays an important role, and impli-
cate the 30-UTR as a major regulatory element in this
process. We have shown that a reporter gene with full
length 30-UTR but lacking a circadian promoter did not
32 Nucleic Acids Research, 2009, Vol. 37,No. 1Figure 4. PTB destabilizes mper2 30-UTR containing mRNA. (A) HeLa cells were transiently transfected with ﬁreﬂy luciferase reporter
construct containing mper2 30-UTR, b-gal as a normalizing control, and the pShuttle-shPTB plasmid for endogenous PTB knock down, with or
without GFP-tagged PTB, and incubated for 24h before treatment with 5mM actinomycin D. Total RNA (1mg) was reverse-transcribed using oligo-
dT primer then quantiﬁed by real-time PCR. Each value was normalized to b-gal activity. The open bar indicates the mRNA level at time 0h of
actinomycin D treatment and the grey bar indicates the mRNA level 6h after actinomycin D treatment. The error bars represent the mean SEM of
three independent experiments. Knocked down and rescued PTB protein levels were validated by western blotting (upper panel). (B) NIH 3T3
cells were transiently expressed with ﬁreﬂy luciferase reporter containing mper2 30-UTR, b-gal as a normalizing control, and siPTB for endogenous
PTB knock down, then incubated for 24h followed by 5mM actinomycin D pulse-chase. Total RNA (1mg) was reverse transcribed using oligo-dT
primer then quantiﬁed by real-time PCR. Each value was normalized to b-gal activity. Open and closed squares indicate transfection with
control siRNA and siPTB-2225, respectively. The error bars represent the mean SEM of three independent experiments. Reduction of PTB protein
level by siRNA was validated by western blotting (upper panel). (C) In vitro transcribed radiolabeled 30-UTR probe was incubated with HeLa
S100 cytoplasmic extract with or without recombinant PTB (100nM) or with competitor oligonucleotide #1 (1mM) for the indicated time. Phenol-
chloroform extracted probes were separated in 7M urea/6%acrylamide gel and subjected to autoradiography (upper panel). Image intensity of each
probe was quantiﬁed by a phosphoimager. The error bars represent the mean SEM of duplicate measurements. (D)I nvitro transcribed 30-UTR
probe was incubated for the indicated times with either wild type (wt) NIH-3T3 S100 cytoplasmic extract or PTB-depleted cell extract (Dep.) with or
without rescue with recombinant PTB (100nM). Phenol-chloroform extracted probes were separated in 7M urea/6%acrylamide gel and subjected
to autoradiography (upper panel). Signal intensity was quantiﬁed by a phosphoimager (lower panel). The error bars represent the mean SEM of
duplicate measurements. PTB depletion of the S100 extract was conﬁrmed by immunoblotting (middle panel).
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mRNA stability is not suﬃcient to generate circadian
oscillation. Although translational repression in mper1
mRNA oscillation has been described (45), this is the
ﬁrst evidence that active mRNA decay plays an important
role in maintaining the mper2 oscillation.
CircadianmRNA decayis regulated by the 3’-UTR
andits binding partners
In general, mRNA decay is mediated by interactions
between a speciﬁc cis-acting element in the mRNA and
its binding partners. Sophisticated regulation of gene
expression involves various factors acting at the post-
transcriptional level, e.g. in splicing regulation, mRNA
export, mRNA degradation and surveilence mechanisms
such as nonsense-mediated mRNA decay (NMD) and
nonstop-mediated mRNA decay (NSD) (48), in addition
to translational regulation. Those regulatory mechanisms
involve many kinds of RNA binding protein including
hnRNPs and splicing-related proteins, and various non-
coding RNAs such as miRNA. We have shown that many
RNA binding proteins interact directly or indirectly with
mper2 mRNA (Figure 3A), suggesting that a single
mRNA can have many diﬀerent binding partners. The
combination of binding proteins on a mRNA molecule
Figure 5. Cytoplasmic PTB shows reciprocal expression pattern with mRNA oscillation. (A) NIH 3T3 cells were treated with 100nM dexametha-
sone, harvested at the indicated times, and cytoplasmic extract prepared for western blot analysis. Cytoplasmic PTB was detected with polyclonal
anti-PTB antibody, and 14-3-3x was included as an internal control. Nuclear lamin B was used as a nuclear marker. The results shown are
representative of three independent experiments. (B) Relative levels of cytoplasmic PTB, normalized to 14-3-3x, were calculated and plotted on
panel B (closed squares) for the 2nd day after treatment. Relative levels of endogenous mper2 mRNA (open diamonds) were also quantiﬁed using the
mouse TATA box binding protein (mtbp) as an internal control for each time point. The results shown are representative of three independent
experiments. Error bars represent the mean SEM. (C) Cytoplasmic PTB in NIH 3T3 cells was observed by staining with polyclonal anti-PTB
antibody at the indicated times after dexamethasone treatment. (D) NIH 3T3 cell cytoplamic extracts prepared at the indicated times after
dexamethasone treatment were subjected to in vitro binding assay with radiolabeled 30-UTR mRNA. Results shown are representative of three
independent experiments. The arrow indicates cytoplasmic PTB binding (upper panel). PTB binding intensities were quantiﬁed by normalization to
GAPDH levels in the same extracts (lower panel). The error bars represent the mean SEM.
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regulation of circadian mRNA oscillation, it is important
to determine which proteins bind to the mRNA, the func-
tion of these proteins, how they interact with each other,
and how they trigger changes in target mRNA metabo-
lism. This study investigated the signiﬁcance of mRNA
decay and dampening-down eﬀect in the regulation of
circadian oscillation with particular emphasis on the role
of cytoplasmic PTB.
The role of increased level of cytoplasmic PTB
We showed that PTB can translocate according to the
circadian phase to perform cytoplasmic functions such
as mRNA degradation. To further elucidate the eﬀects
of PTB on mRNA degradation, it is necessary to examine
what causes the increase in cytoplasmic PTB levels and the
function of PTB in the cytoplasm. Several reports have
suggested that PTB increases target mRNA stability
(23,42); however, we found that PTB had an opposite
eﬀect on mRNA stability. This diﬀerence in action of
PTB may be the result of complex formation with avail-
able RNA binding proteins and generation of stoichio-
metric change within the mRNA-protein complex. UV
cross-linking analysis of mouse SCN nuclear protein
revealed changes in the proﬁle of mRNA binding proteins
during the circadian period (data not shown), indicating
that complex formation between mRNA and its binding
partners can change during circadian phases. Considering
that nucleocytoplasmic shuttling and a broad range of
RNA-binding speciﬁcity are general characteristics of
members of the hnRNP family, the complex relationships
between mRNA and RNA binding proteins such as PTB
may inﬂuence mRNA stability. We cannot exclude the
possibility that other functions of PTB aﬀect circadian
rhythm; since PTB has a broad range of binding capacity
to mRNA, the increase of peak amplitude caused by
depletion of PTB may not be solely caused by inhibition
of mRNA decay.
Circadianoscillation isflexible but enduring
Our experiments demonstrated robust and reproducible
mper2 mRNA oscillation following synchronization with
the modifed dexamethasone treatment. Many reports have
demonstrated that certain physiological treatments or
gene disruptions aﬀect diﬀerent aspects of circadian oscil-
lation such as peak amplitude change in mRNA or protein
oscillation, phase shift in locomotor activity, or even elim-
ination of oscillation (49–51). We found that the oscilla-
tion of mper2 mRNA continued with increased peak
amplitude when the mper2 mRNA binding protein PTB
was depleted. Similar results were reported at both tran-
scriptional and post-transcriptional levels for mRNA reg-
ulation of another circadian gene, aanat (arylalkylamine
N-acetyltranferase; serotonin N-acetyltransferase). When
nocturnal aanat transcription was inhibited by ICER
(inducible cAMP early repressor), robust oscillation con-
tinued with increased peak amplitude and no aﬀect on
circadian phase (52). In addition, reduction of RNA-
binding proteins hnRNP R, Q and L, which have a desta-
bilizing eﬀect on aanat mRNA, also resulted in increased
mRNA amplitude (32). As various regulation mecha-
nisms are involved in the modulation of overt circadian
gene oscillation, regulatory mechanisms besides PTB-
mediated mRNA degradation are probably also involved
in circadian mper2 mRNA oscillation. We previously
reported that the 30-UTR binding protein hnRNP Q
can bind to an IRES (internal ribosomal entry site) ele-
ment in the 50-UTR and modulate nocturnal AANAT
translation (35), showing that a single binding protein
can function in various post-transcriptional mechanisms.
Our present study demonstrates that PTB has a destabiliz-
ing eﬀect on mper2 mRNA, but we assume that addi-
tional, as yet uncharacterized, RNA binding partners
also act in a concerted manner to inﬂuence the fate of
mper2 mRNA.
Circadian oscillation may provide buﬀering capacity
against drastic changes in the molecular environment.
As circadian oscillation is the result of complicated regu-
lation and interconnected regulatory circuits, the oscilla-
tory pattern may not be readily disrupted. Circadian
rhythm is linked to cellular energy metabolism and the
cell cycle, therefore an organism will face serious physio-
logical problems if the regulation of circadian rhythm
Figure 6. PTB down regulation aﬀects mper2 mRNA circadian oscilla-
tion amplitude. (A) Western blot showing reduction of endogenous
PTB in total cell extract from NIH 3T3 cells by PTB siRNA. 14-3-3x
was used as an internal control. The results shown are representative of
three independent experiments. (B) Eﬀect of PTB depletion on endo-
genous mper2 mRNA oscillation. NIH 3T3 cells were transfected
with control siRNA (open squares) or siPTB (closed squares) and
grown to 80% conﬂuency prior to treatment with 100nM dexametha-
sone to synchronize the circadian oscillation (time 0h). Total RNA
(1mg) from each time point was subjected to quantitative real time
RT–PCR with primers speciﬁc to mper2 or mtbp (TATA box binding
protein) as a normalizing control. Results shown are representative
of three independent experiments. The error bars represent the
mean SEM.
Nucleic Acids Research, 2009, Vol. 37, No. 1 35is disturbed. As is the case for many other fundamental
physiological phenomena, the complete regulatory
mechanism controlling circadian rhythms remains to be
revealed.
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